PRAF2作为一种用于乳腺癌的新型生物标志物，经机器学习和实验验证。

PRAF2 as a novel biomarker for breast cancer with machine learning and experimentation validation.

作者信息

Wang Zheng, Bi Zilin, Bo Hongguang, Xu Junyi, Sha Rui, Yin Zhaocai, Yu Changsheng, Xu Yufa, Shi Xiaomeng, Song Wenbo, Chen Bin, Wang Yabing, Zhang Qian, Chen Jianping

机构信息

Department of Thyroid and Breast Surgery, Yijishan Hospital, First Affiliated Hospital of Wannan Medical College, Zheshan West Rd No. 2, Wuhu , Anhui Province, 241001, China.

School of Basic Medical Science, Capital Medical University, No. 10 Right Outside the Western Headlines, Beijing, 100069, China.

出版信息

BMC Cancer. 2025 Jan 8;25(1):32. doi: 10.1186/s12885-024-13258-7.

DOI:10.1186/s12885-024-13258-7

PMID:39773456

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11708060/

Abstract

BACKGROUND

Breast cancer (BC) is the most prevalent malignancy in women. Potential therapeutic targets for BC are of great significance. In our previous study, we found that prenylated rab acceptor 1 domain family member 2 (PRAF2) is an oncogene in BC. However, the exact mechanism of PRAF2 in BC cancer promotion is still not fully understood.

METHODS

Pan-cancer analysis of PRAF2 was performed in the TIMER, Kaplan‒Meier, UALCAN and GEPIA databases.The prognostic value of PRAF2 in BC was investigated in the GEPIA database. The influence of PRAF2 on immune infiltration in BC was analyzed in the TISIDE and TIMER databases. Finally, we validated the expression of PRAF2 in our institutional samples. After downregulating PRAF2 in two BC cell lines, we tested cell proliferation by CCK-8 and Wound healing assays.

RESULTS

PRAF2 was highly expressed in various cancers, including BC, and in most BC cell lines. Higher expression of PRAF2 indicated poorer overall survival (OS) but not disease-free survival (DFS). Higher expression of PRAF2 is an independent prognostic factor in BC.PRAF2 is more highly expressed in BC than in the corresponding normal tissues. Downregulation of PRAF2 in BC can significantly inhibit viability and migration.

CONCLUSIONS

PRAF2 is highly expressed in various cancers, including BC. The expression of PRAF2 is related to Liquid-Liquid Phase Separation in BC. Finally, PRAF2 is upregulated in BC based on our institutional data. Downregulation of PRAF2 significantly inhibits cellular viability、migration in BC. PRAF2 may be a potential biomarker and therapeutic target for BC.

摘要

背景

乳腺癌（BC）是女性中最常见的恶性肿瘤。BC的潜在治疗靶点具有重要意义。在我们之前的研究中，我们发现异戊二烯化的rab受体1结构域家族成员2（PRAF2）是BC中的一种癌基因。然而，PRAF2在BC致癌过程中的确切机制仍未完全阐明。

方法

在TIMER、Kaplan-Meier、UALCAN和GEPIA数据库中对PRAF2进行泛癌分析。在GEPIA数据库中研究PRAF2在BC中的预后价值。在TISIDE和TIMER数据库中分析PRAF2对BC免疫浸润的影响。最后，我们在我们机构的样本中验证了PRAF2的表达。在两种BC细胞系中下调PRAF2后，我们通过CCK-8和伤口愈合试验检测细胞增殖。